Overview

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML

Status:
Recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Vor Biopharma

Treatments:

Gemtuzumab